The International Center for Vaccination (hereinafter referred to as the Center), was organized by the order of the Rector of the Kazakh National Agrarian Research University (hereinafter referred to as the University) on May 2, 2020  in accordance with the Charter of the University. The center is a subdivision of the University, carrying out research work on the specific prevention and treatment of infectious diseases of animals, birds and humans, including allergic diseases. The Center additionally trains of specialists and PhD students in the theoretical and practical foundations of the development, testing and implementation of various generations of vaccines into practice.
 

Director

Tabynov Kaissar Kazybayevich (http://orcid.org/0000-0001-5823-1280, Hirsch index - 10), is an expert in the field of vaccinology. His main specialization is associated with the development, study and implementation of  the production of various vaccines for animals, birds and humans. As a result of his 17 years of scientific activity, 3 vaccines for public health were developed (Refluvac - against pandemic influenza A / H1N1pdm09; Kazfluvac - against pandemic influenza A / H5N1; and Kazfluvir - against seasonal influenza) and 7 vaccines for veterinary medicine (against highly pathogenic avian influenza H5 subtypes and H7, equine influenza, bovine and small bovine brucellosis). Most (about 60%) of these developments have been introduced and are widely used in practice or are at the stage of implementation in production. He was directly involved in preclinical research and the registration of the two Kazakhstani pandemic vaccines, Refluvac and Kazfluvac (registration certificates RK-BP-3 №. 019910 and RK-BP-3 №. 019911 dated 05.28.2013), and also led the pilot production of a vaccine against seasonal influenza Kazfluvir, which has successfully passed the III-phase clinical trial in Kazakhstan. Under his leadership, in January 2019, a new vaccine against bovine brucellosis based on influenza viral vectors, which has no analogues in the world, was put into practice in Kazakhstan (registration certificate №. RK-VP-1-3775). Currently, under his leadership, research is underway on the creation of COVID-19 vaccines for health and veterinary medicine, as well as a vaccine against allergic rhinitis and bronchial asthma caused by wormwood pollen.

K. Tabynov, within the framework of the Bolashak International Scholarship Program, underwent a one-year internship (postdoctoral study) at the biotechnological company Vaxine Pty Ltd (Adelaide, Australia) on the topic: “Innovative technologies for the creation of safe and highly effective vaccines for health care”. As part of this internship, he also studied the fundamentals of Good Laboratory Practice (GLP) Preclinical Vaccine Trials and Good Clinical Practice (GCP) Human Clinical Trials.
           
Due to his significant contribution to the development of Kazakhstani science,  K. Tabynov was awarded a number of awards, prizes and scholarships.
           
There is detailed information about this on his LinkedIn page accessible using the following link: https://www.linkedin.com/in/kaissar-tabynov-16082937/

Contact details:
tabynov_81@mail.ru
ktabynov@gmail.com
kaissar.tabynov@kaznaru.edu.kz

     
Leading Researcher
         
Tabynov Kairat Kazybayevich (Ph.D) (http://orcid.org/0000-0001-9411-7952, Hirsch index - 6), is a highly qualified specialist in the field of biological safety, immunology and virology. He is also an expert of the Institutional Committee for the Care and Use of Laboratory Animals (IACUC) of the Central Reference Laboratory of  the  «Masgut Aikimbayev’s National Scientific Center for Especially Dangerous Infections» of  the Ministry of Healthcare of  the Republic of Kazakhstan. Within the framework of the international scholarship program of Norman Borlaug (Borlaug Fellowship Program), he passed a 3-month internship at Ohio State University (Worcester, USA) to obtain and test nanovaccines against influenza. Tabynoy K.K. is one of the developers of two vaccines against COVID-19 (NARUVAX C-19 and NARUVAX C-19 / Nano) for healthcare , a vaccine against SARS-CoV-2 (NARUVAX C-19 (pets)) for veterinary medicine, and a vaccine against allergic rhinitis and bronchial asthma caused by wormwood pollen.
         
For his work in science,  significant contributions to the development of diagnostic and prophylactic drugs against dangerous viral infectious diseases, the development of a number of vaccines (inactivated, attenuated and subunit) for public health and veterinary medicine, he was awarded a prize and a diploma of the Republican competition of achievements in the field of invention “Shapagat- 2011 "in the" Youngest Inventor "nomination and was awarded state scientific scholarships (for talented young scientists MES RK-2015; for outstanding scientists MES RK-2020). He has published over 80 scientific papers, including 10 articles in journals indexed in Scopus and WoS, 1 Eurasian and 27 national patents, and 1 monograph. He is currently the scientific advisor of one PhD doctoral student at Satbayev University.

Contact details:
kairat.tabynov@gmail.com
tabynov777@mail.ru
kairat.tabynov@kaznaru.edu.kz
 


Senior Researcher

Nurpeisov Tair Temirlanovich

A professor and allergist-immunologist, Nurpeisov is the head of the Republican Allergological Center, a Senior Researcher of the International Center for Vaccinology, the Chairman of the Society of "Allergologists, Immunologists, Immunorehabilitation specialists" and the Chief Allergologist of Almaty, Doctor of Medical Sciences, PhD.

He graduated from the Asfendiyarov Kazakh National Medical University, studied his clinical residency at KazNMU and has authored over 100 publications.

Overall, Nurpeisov has work experience totaling over 20 years. He is a member of the European Academy of Allergology and Clinical Immunology (EAACI), a “golden” member of the European Respiratory Society (ERS), a member of the Society of Physicians of the Republic of Kazakhstan, and a member of the Euro-Asian Respiratory Society (EAPO). He was also awarded the Medal of the Ministry of Health of the Republic of Kazakhstan "For contribution to health care" (2016) and the medal of the Ministry of Health of the Republic of Kazakhstan "Excellence in Healthcare" (2019).
  
Contact details:
dr.tt@mail.ru

 
Senior Researcher

Bugybayeva Dina Askarovna

Since the beginning of 2021, she has been a senior researcher at the International Center for Vaccinology, (https://orcid.org/0000-0003-1891-2748).

Currently, Dina is undergoing an internship at Ohio State University, working as a visiting researcher for training in the evaluation of candidate vaccines against influenza (H1N1 SwIV), salmonellosis and coronavirus (SARS-CoV-2).

Dina specializes in immunology and virology. In 2017, she graduated from the University of Edinburgh, Roslin Institute under the Master of Science in Animal Biological Sciences program on the Bolashak International Scholarship.

The topic of her master’s thesis was "Study of the immunoregulatory effect of the Trem2 gene on bone marrow macrophages".
 
Contact details:
Bdina85@mail.ru
 
 
 
 
Senior Researcher

Matikhan Nurali, doctor of Veterinary Sciences (PhD), is a senior researcher at the International Center for Vaccinology of the Kazakh National Agrarian Research University.

He is the author of more than 30 scientific papers, including 3 methodological recommendations and 4 copyright certificates for inventions. He is the author of 3 scientific papers in foreign publications and the winner of several prizes for foreign scientists. He has published articles in scientific journals based in the People's Republic of China.
  
Contact details:
Nurik200886@mail.ru

 
Specialist

Babaeva Meruert Erzhangyzy, is a doctor-allergist, and a PhD student of  KazNMU , thesis topic is entitled: "Conducting and testing on a mouse model of a new formulation of an allergic vaccine for an ultra-short regime of allergen-specific immunotherapy." She is a specialist at the International Center for Vaccinology. Her research work is carried out within the framework of the project IRN AP08051924 "Development of a new formulation of an allergic vaccine for subcutaneous allergen-specific immunotherapy".

She is a member of the Society of Allergologists, Immunologists, Immunorehabilitologists.

She has more than 10 scientific and scientific-methodical works.

Refresher courses:
2018 - Allergen - specific immunotherapy, 3 hours, Almaty;
2019 - Functional studies of the respiratory system and modern technologies for the delivery of inhalation drugs, 4 hours, Almaty;
2019 - Immunogram  in clinical practice. Application and interpretation, 4 hours, Almaty;
2019 - Prevention of drug hypersensitivity. Specific allergy diagnostics in vitro and in vivo in everyday practice, 4 hours, Almaty;
2019 - Immunodiagnostics, immunotherapy and immunoprophylaxis in the practice of a modern doctor, 54 hours, Almaty;
2019 - Hospital infection. New approaches. Express diagnostics. The newest rational antibacterial therapy, 21 hours, Almaty;
2020 - Basics of  biosafety and  biosecurity in laboratories of the Republic of  Kazakhstan, 54 hours, «Masgut Aikimbayev’s National Scientific Center for Especially Dangerous Infections» of  the Ministry of  Healthcare of  the Republic of Kazakhstan, Almaty;
2021 - The use of  laboratory animals in the experiment, 40 hours, «Masgut Aikimbayev’s National Scientific Center for Especially Dangerous Infections» of  the Ministry of  Healthcare of  the Republic of Kazakhstan, Almaty;
2021 - Spirometry using modern technologies during a pandemic, 4 hours, Almaty.

Contact details:
meruert-babaeva@mail.ru

Junior Researcher

Rakhmatullaeva Guliza Talgatkyzy has a master of Science in Biotechnology from Al-Farabi Kazakh National University. Rakhmatullayeva Guliza Talgatkyzy has been an employee of the International Center for Vaccinology at the Kazakh National Agrarian Research University since 2021, and is currently working as a Junior researcher.
• Fellow of the Abay-Vern program;
“Global quality in European livestock production products”, Clermont-Auverne University, France;
Specialization: Territory and Local Development Management;
• Scientific internship at INRAE ​​- National Research Institute of Agriculture, Food and Environment, France;
• She has 1 Article in journals included in the Scopus database;
• In 2019, she was the winner in as competition for the best scientific work of students in the natural-technical, social, technical and economic sciences at KazNU.

Work-related skills:
• works with proteins (sanitation, measurement of protein concentration, protein purification by chromatography) and protein analysis (electrophoresis, immunoblotting);
• works with DNA, RNA and plasmids (isolation of  DNA, RNA, PCR, vector construction (methods of molecular biology), two-hybrid analysis (in a yeast system);
• setting of ELISA analysis (infections, hormones, tumor markers);
• production of polyclonal antibodies (protein purification using affinity chromatography, antigen injection to a rabbit, antibody purification).
Contact details:
guliza9676@gmail.com


Junior Researcher
Orynbasar Madiana Bolatzhankyzy has a master's degree in veterinary medicine and is currently a PhD student at KazNAIU, with the thesis topic: "Subunit COVID-19 vaccine for domestic cats: obtaining and studying immunobiological properties."
Orynbasar Madiana Bolatzhankyzy has been an employee of the International Center for Vaccinology at the Kazakh National Agrarian Research University since 2021, and is currently a Junior Researcher.
In 2020 she defended her masters’ thesis on the topic "Improving the technology for the development of diagnostic anti-rabies immunoglobulin."
Refresher courses:
2020 - Epizootology, modern methods of diagnostics and prevention of infectious animal diseases, "FGU" Center for Veterinary Medicine Russia, St. Petersburg.
2020 - "Technology of biological preparations used for diagnostics, treatment and prevention of farm animals", Research and Production Enterprise "ANTIGEN" Kazakhstan, Almaty.
2020 - "Legal aspects of pharmaceutical activities carried out by organizations in the field of circulation of medicinal products intended for animals", "Center for advanced training of veterinary specialists" - a specialized structural educational unit of ANO "Vetpharmaceuticals" Russia.
2020 - Veterinary Safety Overall View, Tecnology University Putra, Department of Food, Science and Technology / Putra, Malaysia.
She has had more than 15 scientific and scientific-methodical works published, including 8 patents.
The level of English language of Orynbasar M.B. is "TOEFL IBT-75".

Contact details:
madiana_95@mail.ru

Laboratory Manager

Yelchibayeva Leila Serikkaliyevna is a specialist in veterinary medicine, and is a master's student of KazNAIU in the area of “veterinary medicine”.
In 2021, she defended her thesis on the topic "Diagnosis of rabies and technology for obtaining a kit for the precipitation reaction".
The direction of her scientific activity and the topic of her master's thesis relates to obtaining and investigating the immunogenicity and protective effectiveness of a subunit vaccine against SARS-CoV-2 infection in cats.
From 2019 to 2021, she held a professional and pre-graduate internship at the Scientific and Production Enterprise “Antigen” in Almaty and in the Uygur district branch of the Republican Veterinary Laboratory, Chunja village.
Since 04.22.2021 she has been working at the International Center for Vaccinology at the Kazakh Agrarian Research University.
Since 2.11.2021 she has been a member of the Council of Young Scientists of the Kazakh National Agrarian Research University.
She presented 1 scientific article at the seventh International scientific and practical conference in Nur-Sultan “Science and education in the modern world: challenges of the XXI century”, including 3 patents published.
Refresher courses:
2021- The use of laboratory animals in an experiment, 40 hours, «Masgut Aikimbayev’s National Scientific Center for Especially Dangerous Infections» of  the Ministry of  Healthcare of  the Republic of Kazakhstan, Almaty.

Contact details:
leila7@inbox.ru

Laboratory assistant

Fomin Gleb Igorevich, has a Master of Natural Sciences and is a laboratory assistant at the International Center for Vaccinology, engaged in histological studies of tissues of model animals.
Since 2017, he has been an active participant and the main organizer of the club "Young Researcher's Club" of the Faculty of Biology and Biotechnology of KazNU, where lectures are given in a popular scientific format on modern problems of biology.
In the period from 2018 to 2019, he held the position of a laboratory assistant-histologist at the pathomorphological research and production laboratory "Consultant Biotech", where he was engaged in the manufacture of immunohistochemical preparations and carried out communication with cancer patients.
From 2020 to 2021, he was an employee of the "Scientific Center for Anti-Infectious Drugs", where preclinical tests of the domestic drug FS-1 were carried out.
Since 2021, he has been a member of the research group engaged in the project "Study of the early immune response in COVID-19 on a model of Syrian hamsters with chronic inflammation and preventive activity of metformin" (IRN AP09259865) at the «Masgut Aikimbayev’s National Scientific Center for Especially Dangerous Infections» of  the Ministry of  Healthcare of  the Republic of Kazakhstan.

Contact details:
gleb.fomeen@gmail.com

1. NARUVAX-C19 and NARUVAX-C19/Nano vaccines are included in the WHO registry as candidate vaccines.
2. 4 strains of the SARS-CoV-2 virus related to the Wuhan, alpha and delta variants were isolated, deposited and characterized by genetic and biological properties.
3. A national patent was obtained (No. 34974 of 26.03.2021) for the SARS-CoV-2 virus strain, and an application was filed (No. 2021/0565.1 of 20.09.2021) for a patent on a method for obtaining a vaccine against COVID-19.
4. Tested and evaluated on a contractual basis 7 medicinal, diagnostic and disinfectants against the virus SARS-CoV-2, and thereby support the developers in the fight against the pandemic COVID-19.
5. Published in the period 2020-2021 years 10 articles in journals of Q1-2(WoS), and a Preprint of an article on the topic: "An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission", which is currently being reviewed in the journal under the Nature portfolio section.
6. 3 PhD doctoral students are being trained in the field of "vaccinology".
 

1. IRN AP08051924 "Development of a new formulation of an allergic vaccine for subcutaneous allergen-specific immunotherapy"
By priority: Life and Health Science.
According to the sub-priority: 5.2. Biotechnologies in medicine; 5.2.5. New biotechnologies for obtaining bio- and medicinal products for preventive medicine.
Funded by: State Institution "Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan".
Years of implementation: 2020-2022.
The total amount of the project is 72,908,000.00 tenge (seventy-two million nine hundred and eight thousand) tenge, including by year:
-for 2020 - in the amount of 24,000,000 tenge (twenty-four million) tenge;
-for 2021-in the amount of 24,400,000 tenge (twenty-four million four hundred thousand) tenge;
-for 2022 -in the amount of 24,508,000 tenge (twenty-four million five hundred and eight thousand) tenge.
The global prevalence of allergic diseases and, at the same time, the disadvantages of commercially available allergen-specific immunotherapy (ASIT) methods makes it necessary to look for new or improved specific treatments of allergies.
Many approaches to improving the ASIT are currently under development, among them the most promising in terms of improving the existing protocols of subcutaneous ASIT is the approach based on the use of adjuvants. With the help of adjuvants, it is possible to significantly reduce the doses of allergens, as well as the number of their injections, which has a positive impact on the safety of this ASIT method. However, the problem is that the most commonly used today (in about 75% of cases) adjuvants of hydroxide or phosphate aluminum have some serious drawbacks, such as the induction of TH2 immune response at the beginning of immunotherapy, neurological pathologies, as well as local undesirable reactions. Therefore, the search for new adjuvants without these drawbacks is an urgent task in the treatment of allergic diseases.
A proposed solution to this problem is the development of a novel allergic vaccine formulation for subcutaneous ASIT based on the innovative AdvaxTM adjuvant or its modification SM55.2™. One of these adjuvants is expected to significantly improve the current protocols for subcutaneous ASIT of allergic rhinitis and bronchial asthma, increasing not only the safety and therapeutic efficacy of the method, but also its convenience for patients.
Technologically, a significant advantage of the proposed novel vaccine formulation is that it is formulated by routinely mixing commercial allergens with AdvaxTM/SM55.2™ adjuvant just before use in the treatment room. Potential consumers of the project results are public and private medical clinics providing ASIT services, as well as producers of commercial allergens.
The objective of the project is to develop and test a potentially effective, safe and convenient novel allergic vaccine formulation for subcutaneous ASIT of rhinitis and bronchial asthma on a mouse model.
Project tasks:
1) Development of a mouse model of allergic rhinitis and bronchial asthma;
2) Obtaining, testing, and selecting the most effective allergic vaccine formulation for subcutaneous ASIT;
3) Development of the optimal subcutaneous ASIT mode with the selected allergic vaccine formulation on the mouse model;
4) Conducting preclinical studies of the novel allergic vaccine formulation for subcutaneous ASIT.
According to the results of the project research at least 2 (two) articles will be published in peer-reviewed international journals, indexed by Web of Science (from 1-3 quartiles) or having a Cite Score percentile in Scopus database at least 35. In addition, it is planned to obtain one national patent for intellectual property products resulting from the project.
From a scientific perspective, the results of this project are expected to contribute to the development of many other studies aimed at creating new or improving existing ASITs, and thus to influence the allergic field of science. In the long term, the project may contribute to the improvement of the Kazakhstan population's health, the development of allergic services (which are in their infancy) and the reduction of the number of complicated forms of allergic diseases in the future, as well as improving the quality of people life with allergies in general.
This will be addressed through the introduction of a new ASIT method in medical practice, which, due to its advantages, should be in demand in the domestic market of medical services. The project will also train highly qualified specialists in the field of allergology or vaccinology.
Potential consumers of the project results are public and private medical clinics providing ASIT services, as well as producers of commercial allergens.
The results of the project will be disseminated to potential users, scientific communities and the general public through publications in leading peer-reviewed journals, reports at national (including those organized by the authorized body) and international conferences, as well as through scientific (Research Gate) and public (facebook) social networks on the Internet. The results of this project will be widely reported in the media, which will lead to the promotion of ASIT as the most appropriate and cost-effective way to treat allergic diseases.
Following the results of the project implementation, the requirement of the contest administrator to submit an application for regional, national and (or) international scientific contests for continuation of research in the chosen scientific direction will also be fulfilled.  


2. IRN AP09259609 "A new platform for intranasal SARS-CoV-2 vaccine based on nanoparticles: design development and testing on laboratory animal models"
By priority: The science of life and Health.
According to the sub-priority: SARS CoV-2 (COVID-19) and other potentially pandemic infectious agents.
Funded by: State Institution "Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan".
Years of implementation: 2021-2023.
The total amount of the project is 69,772,258 tenge (sixty-nine million seven hundred seventy-two thousand two hundred fifty-eight ) tenge, including by year:
-for 2021 - in the amount of 19,926,746 tenge (nineteen million nine hundred twenty-six thousand seven hundred forty-six) tenge;
-for 2022 -in the amount of 24,964,647 tenge (twenty-four million nine hundred sixty-four thousand six hundred forty-seven) tenge;
-for 2023-in the amount of 24,880,865 tenge (twenty-four million eight hundred eighty thousand eight hundred sixty-five) tenge.
As a new platform for intranasal SARS-CoV-2 vaccine, the research group of the project proposes to develop and test a design based on chitosan nanoparticles with mannose. The complex of these natural biocompatible polymers, in addition to the ideal transportation of the protein subunits into the mucous membranes, also have a pronounced adjuvant effect. This nanoparticle vaccine formulation was obtained by our panthers at Ohio State University (OSA, USA), and was previously used to develop vaccines against swine flu and poultry salmonellosis. To enhance the T-cell immune response of the nanoparticle vaccine formulation, it is planned to include the adjuvant CpG55.2. (antagonist of the Toll-like receptor 9) developed on the basis of artificial intelligence by our other partner Vaxine Pty Ltd (Adelaide, Australia).
This adjuvant has its unique sequence and is used as an important component of the subunit SARS-CoV-2 vaccine under the trade name COVAX-19 (developer is Vaxine Pty Ltd), which has successfully passed Phase I clinical trial with 40 volunteers in Australia, and is now preparing for Phase II-III clinical trials in 10 countries worldwide. It is important to note that this adjuvant has the potential to reduce the antigenic load of the vaccine by more than 400 times.
The main idea of the proposed project is to combine two advanced technologies for intranasal delivery of antigens based on nanoparticles and adjuvant CpG55.2 (TLR-9 antagonist) to create a new platform for safe, effective and non-injectable SARS-CoV-2 vaccine. Achieving the latter makes it possible to eliminate a number of issues (pain, cross-contamination, needle damage, insufficient or over-dosing, increased costs, as well as fear of injections) associated with vaccination.
The aim of the project is to develop a novel safe, immunogenic and effective platform for SARS-CoV-2 nanoparticle vaccine with intranasal administration.
In order to achieve the objective, the following tasks are set:
1) Construction and generation of recombinant S1/RBD proteins of SARS-CoV-2 virus;
2) Development of a laboratory animal model to evaluate the vaccine effectiveness;
3) Obtaining safe and effective SARS-CoV-2 nanoparticle vaccine formulations for intranasal application;
4) SARS-CoV-2 nanoparticle vaccine stability assessment in storage and transport conditions;
5) Study of immunobiological properties of SARS-CoV-2 vaccine on laboratory animal model.
A novel safe, immunogenic and effective SARS-CoV-2 nanoparticle vaccine platform with intranasal application will be developed. This platform will include two advanced technologies from our international partners - intranasal delivery of antigens based on nanoparticles and adjuvant CpG55.2 (TLR-9 antagonist).
New scientific data on safety, immunogenicity and efficacy of the novel vaccine platform in different laboratory animal models will be obtained. A minimum of 1 (one) original or review paper will be published in a peer-reviewed journal included in 1 (first) quartile (Q1) in the Web of Science and/or having a CiteScore percentile in the Scopus database of at least 80 (presumably in Vaccine [percentile 98; https://www.journals.elsevier.com/vaccine] or npj Vaccines [percentile 87; https://www.nature.com/npjvaccines/] or other), and one application for an invention will be submitted to the National Patent Office. In case of success, the created platform may serve first as a subject for investment and then licensing by local and possibly global pharmaceutical companies (foreign partners of the project will support this). It may also serve as a basis for developing vaccines against other respiratory viral infections, including those with pandemic potential.
It is expected that the updated SARS-CoV-2 virus recombinant S1/RBD proteins will be purchased by the Kazakhstan diagnostic company OMICRON 3D LLP, which plans to use them to increase the sensitivity and specificity of its COVID-19 ELISA kits. Due to its interest, this company is acting as a private partner of the proposed project and has signed a corresponding co-financing agreement.
The project aims to counteract the current COVID-19 and future pandemics with the use of advanced technologies, and therefore is in line with the global scientific practices world science trend. Therefore, its implementation will allow increasing the level and potential of research works, as well as the competitiveness of KZ Kazakhstani scientific organizations and their teams.

Publications of the center's employees
 
1. Kaissar Tabynov, Zhailaubay Kydyrbayev, Sholpan Ryskeldinova, Bolat Yespembetov, Nadezhda Zinina, Nurika Assanzhanova, Yerken Kozhamkulov, Dulat Inkarbekov, Tatyana Gotskina, Abylai Sansyzbay.Novel influenza virus vectors expressing Brucella L7/L12 or Omp16proteins in cattle induced a strong T-cell immune response, as well ashigh protectiveness against B. abortus infection. Vaccine.Volume 32, Issue 18, 11 April 2014, Pages 2034-2041. https://doi.org/10.1016/j.vaccine.2014.02.058.
 
2. Kaissar Tabynov, Abylai Sansyzbay, Zhailaubay Kydyrbayev, Bolat Yespembetov, Sholpan Ryskeldinova, Nadezhda Zinina, Nurika Assanzhanova, Kulaisan Sultankulova, Nurlan Sandybayev, Berik Khairullin, Irina Kuznetsova, Boris Ferko, Andrej Egorov. Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection. Virol J 11, 69 (2014).https://virologyj.biomedcentral.com/articles/10.1186/1743-422X-11-69.
 
3. Kaissar Tabynov, Bolat Yespembetov, Abylai Sansyzbay. Novel vector vaccine against Brucella abortus based on influenza A viruses expressing Brucella L7/L12 or Omp16 proteins: Evaluation of protection in pregnant heifers. Vaccine.Volume 32, Issue 45, 14 October 2014, Pages 5889-5892. https://doi.org/10.1016/j.vaccine.2014.08.073.
 
4. K Tabynov, Zh Kydyrbayev, Sh Ryskeldinova, N Assanzhanova, A Sansyzbay. Duration of the protective immune response after prime and booster vaccination of yearlings with a live modified cold-adapted viral vaccine against equine influenza.vaccine.2014.03.095. https://doi.org/10.1016/j.vaccine.2014.03.095.

5. Kaissar Tabynov, Sholpan Ryskeldinova, Abylai Sansyzbay. An influenza viral vector Brucella abortus vaccine induces good cross-protection against Brucella melitensis infection in pregnant heifers. vaccine.2015.06.045. https://doi.org/10.1016/j.vaccine.2015.06.045.

6. Indira Akzhunusova, Nurika Assanzhanova, Kaissar Tabynov, Buryl Abdrakhmanova, Abilai Sansyzbay. Optimization of influenza A and B viruses cultivation conditions for preparation of trivalent seasonal influenza split vaccine. International Journal of Pharmaceutical Sciences and Research.10.13040/IJPSR.0975-8232.6(6).2375-81.

7. Anne Jackson, K Tabynov, Z Kydyrbayev, S Ryskeldinova, N Assanzhanova, Y Kozhamkulov, D Inkarbekov, A Sansyzbay. Safety and immunogenicity of a novel cold-adapted modified-live equine influenza virus vaccine (vol 92, pg 450, 2014). AUSTRALIAN VETERINARY JOURNAL, 2015.

8. Kaissar Tabynov, Bolat Yespembetov, Nurali Matikhan, Sholpan Ryskeldinova, Nadezhda Zinina, Zhailaubay Kydyrbayev, Nurika Assanzhanova, Kairat Tabynov, Gourapura J Renukaradhya, Gulnara Mukhitdinova, Abylai Sansyzbay. First evaluation of an influenza viral vector based Brucella abortus vaccine in sheep and goats: Assessment of safety, immunogenicity and protective efficacy against Brucella melitensis infection.vetmic.2016.11.001. https://doi.org/10.1016/j.vetmic.2016.11.001.

9. Kaissar Tabynov, Bolat Yespembetov, Sholpan Ryskeldinova, Nadezhda Zinina, Zhailaubay Kydyrbayev, Yerken Kozhamkulov, Dulat Inkarbekov, Abylai Sansyzbay. Prime-booster vaccination of cattle with an influenza viral vector Brucella abortus vaccine induces a long-term protective immune response against Brucella abortus infection.vaccine.2015.12.028. https://doi.org/10.1016/j.vaccine.2015.12.028.

10. Kaissar Tabynov. Influenza viral vector based Brucella abortus vaccine: a novel vaccine candidate for veterinary practice. Expert review of vaccines.,2016.

11. Kaissar Tabynov, Sholpan Ryskeldinova, Zhailaubay Kydyrbayev, Abylai Sansyzbay. Safety of the novel influenza viral vector Brucella abortus vaccine in pregnant heifers. CIENCIA RURAL,2016.

12. Kairat Tabynov, Abylay Sansyzbay, Zhanara Tulemissova, Kaissar Tabynov, Santosh Dhakal, Aigul Samoltyrova, Gourapura J Renukaradhya, Muratbay Mambetaliyev. Inactivated porcine reproductive and respiratory syndrome virus vaccine adjuvanted with Montanide™ Gel 01 ST elicits virus-specific cross-protective inter-genotypic response in piglets. vetmic.2016.06.014. https://doi.org/10.1016/j.vetmic.2016.06.014.

13. Kaissar Tabynov, Mukhit Orynbayev, Gourapura J Renukaradhya, Abylai Sansyzbay. Simultaneous subcutaneous and conjunctival administration of the influenza viral vector based Brucella abortus vaccine to pregnant heifers provides better protection against B. abortus 544 infection than the commercial B. abortus S19 vaccine.vaccine.2016.08.072. https://doi.org/10.1016/j.vaccine.2016.08.072.

14. Aigerim Mailybayeva, Bolat Yespembetov, Sholpan Ryskeldinova, Nadezhda Zinina, Abylai Sansyzbay, Gourapura J Renukaradhya, Nikolai Petrovsky, Kaissar Tabynov. Improved influenza viral vector based Brucella abortus vaccine induces robust B and T-cell responses and protection against Brucella melitensis infection in pregnant sheep and goats. PLoS One,2017. https://doi.org/10.1371/journal.pone.0186484.

15. NN Asanzhanova, Sh Zh Ryskeldinova, OV Chervyakova, BM Khairullin, MM Kasenov, KK Tabynov. Comparison of different methods of purification and concentration in production of influenza vaccine. Bulletin of Experimental Biology and Medicine volume 164, pages229–232 (2017).

16. Mukhit B Orynbayev, Sasan Fereidouni, Abylay R Sansyzbai, Bakhytkul A Seidakhmetova, Vitaliy M Strochkov, Askar M Nametov, Sandugash O Sadikaliyeva, Asel Nurgazieva, Kaissar K Tabynov, Nurkuysa M Rametov, Kulyaisan T Sultankulova. Genetic diversity of avian avulavirus 1 (Newcastle disease virus genotypes VIg and VIIb) circulating in wild birds in Kazakhstan.Archives of  Virology volume 163, pages1949–1954 (2018).

17. Kuandyk Zhugunissov, Yerbol Bulatov, Dmitriy Taranov, Zakir Yershebulov, Zhumagali Koshemetov, Asankadyr Zhunushov, Gourapura J Renukaradhya, Kaissar Tabynov, Yergali Abduraimov. Beta-propiolactone inactivated bivalent bluetongue virus vaccine containing Montanide ISA-71VG adjuvant induces long-term immune response in sheep against serotypes 4 and 16 even after 3 years of controlled vaccine storage.vetmic.2018.10.003. https://doi.org/10.1016/j.vetmic.2018.10.003.

18. Ainur Nurpeisova, Markhabat Kassenov, Nurkuisa Rametov, Kaissar Tabynov, Gourapura J Renukaradhya, Yevgeniy Volgin, Altynay Sagymbay, Amanzhol Makbuz, Abylay Sansyzbay, Berik Khairullin. Analysis of the efficacy of an adjuvant-based inactivated pandemic H5N1 influenza virus vaccine. Archives of Virology volume 164, pages1027–1036 (2019).

19. Dina Bugybayeva, Sholpan Ryskeldinova, Nadezhda Zinina, Makhpal Sarmykova, Nurika Assanzhanova, Zhailaubay Kydyrbayev, Kaissar Tabynov. Development of Human Vectored Brucellosis Vaccine Formulation: Assessment of Safety and Protectiveness of Influenza Viral Vectors Expressing Brucella Immunodominant Proteins in Mice and Guinea Pigs. BioMed Research International.Volume 2020 |Article ID 1438928 .  https://doi.org/10.1155/2020/1438928.

20. Jagadish Hiremath, Sankar Renu, Kaissar Tabynov, Gourapura J Renukaradhya. Pulmonary inflammatory response to influenza virus infection in pigs is regulated by DAP12 and macrophage M1 and M2 phenotypes. cellimm.2020.104078. https://doi.org/10.1016/j.cellimm.2020.104078.

21. Aigerim Mailybayeva, Sholpan Ryskeldinova, Nadezhda Zinina, En-Min Zhou, Gourapura J Renukaradhya, Kaissar Tabynov. Evaluation of Duration of Immunogenicity and Protective Efficacy of Improved Influenza Viral Vector–Based Brucella abortus Vaccine Against Brucella melitensis Infection in Sheep and Goats. Front. Vet. Sci., 27 February 2020. https://doi.org/10.3389/fvets.2020.00058.

22. Dina Bugybayeva, Zhailaubay Kydyrbayev, Nadezhda Zinina, Nurika Assanzhanova, Bolat Yespembetov, Yerken Kozhamkulov, Kunsulu Zakarya, Sholpan Ryskeldinova, Kaissar Tabynov. A new candidate vaccine for human brucellosis based on influenza viral vectors: a preliminary investigation for the development of an immunization schedule in a guinea pig model. Infectious Diseases of Poverty volume 10, Article number: 13 (2021). https://doi.org/10.1186/s40249-021-00801-y.

23. Kenneth Yeh, Falgunee K Parekh, Kairat Tabynov, Kaissar Tabynov, Roger Hewson, Jeanne Marie Fair, Sandra Simone Essbauer, John Hay. Operationalizing cooperative research for infectious disease surveillance: lessons learned and ways forward. Frontiers in Public Health, 2021. https://www.frontiersin.org/articles/10.3389/fpubh.2021.659695/pdf.

24. Sholpan Ryskeldinova, Nadezhda Zinina, Zhailaubay Kydyrbayev, Bolat Yespembetov, Yerken Kozhamkulov, Dulat Inkarbekov, Nurika Assanzhanova, Aigerim Mailybayeva, Dina Bugybayeva, Makhpal Sarmykova, Berik Khairullin, Kairat Tabynov, Aitbay Bulashev, Batyrbek Aitzhanov, Khairulla Abeuov, Abylay Sansyzbay, Tlekles Yespolov, Gourapura J Renukaradhya, Steven Olsen, Angel Oñate, Kaissar Tabynov. Registered Influenza Viral Vector Based Brucella abortus Vaccine for Cattle in Kazakhstan: Age-Wise Safety and Efficacy Studies. Front. Cell. Infect. Microbiol., 01 July 2021 . https://doi.org/10.3389/fcimb.2021.669196.

25. Lu Zhang, Lizhen Wang, Shuaishuai Cao, Huanhuan Lv, Jingjing Huang, Guixi Zhang, Kaissar Tabynov, Qin Zhao, En-Min Zhou. Nanobody Nb6 fused with porcine IgG Fc as the delivering tag to inhibit porcine reproductive and respiratory syndrome virus replication in porcine alveolar macrophages. Veterinary Research volume 52, Article number: 25 (2021). https://doi.org/10.1186/s13567-020-00868-9.

26. Kenneth B Yeh, Kairat Tabynov, Falgunee K Parekh, Illich Mombo, Kyle Parker, Kaissar Tabynov, Shelton S Bradrick, Ashley S Tseng, Ji-Rong Yang, Lolly Gardiner, Gene Olinger, Bradly Setser. Significance of High-Containment Biological Laboratories Performing Work During the COVID-19 Pandemic: Biosafety Level-3 and -4 Labs. Front. Bioeng. Biotechnol., 13 August 2021. https://doi.org/10.3389/fbioe.2021.720315.

27. Sankar Renu, Heather L Wilson, Kaissar Tabynov, Jagadish Hiremath. Editorial: Engineered Adjuvants and Carriers for an Animal Infectious Disease Vaccine. Front Bioeng Biotechnol. 2021; 9: 692634. https://www.frontiersin.org/articles/10.3389/fbioe.2021.692634/full.

28. Kairat Tabynov, Nurkeldi Turebekov, Meruert Babayeva, Gleb Fomin, Toktasyn Yerubaev, Tlektes Yespolov, Lei Li, Gourapura Renukaradhya, Nikolai Petrovsky, Kaissar Tabynov. An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission.Research Square,2021. https://assets.researchsquare.com/files/rs-902649/v1_covered.pdf?c=1632251785.

29. Kairat Tabynov, Madiana Orynbassar, Leila Yelchibayeva, Nurkeldi Turebekov, Toktassyn Yerubayev, Nurali Matikhan, Tlektes Yespolov, Nikolai Petrovsky, Kaissar Tabynov. A Spike protein-based subunit SARS-CoV-2 vaccine for pets: safety, immunogenicity, and protective efficacy in juvenile cats. Preprint from Research Square, 16 Nov 2021. https://assets.researchsquare.com/files/rs-1083984/v1/8ab19b57-1baa-4b23-ba29-4b4691fba4af.pdf?c=1637093834.

30. Kenneth B Yeh, Kairat Tabynov, Falgunee K Parekh, Elina Maltseva, Yuriy Skiba, Zhanna Shapiyeva, Ablay Sansyzbai, Stefan Frey, Sandra Essbauer, Roger Hewson, Allen L Richards, John Hay. Building Scientific Capability and Reducing Biological Threats: The Effect of Three Cooperative Bio-Research Programs in Kazakhstan. Front. Public Health, 12 October 2021. https://doi.org/10.3389/fpubh.2021.683192.

31. Kuandyk Zhugunissov, Sanat Kilibayev, Muratbay Mambetaliyev, Kunsulu Zakarya, Markhabat Kassenov, Yergaliy Abduraimov, Yerbol Bulatov, Moldir Azanbekova, Zharkinay Absatova, Khairulla Abeuov, Ryspek Nurgaziev, Gourapura J Renukaradhya, Kairat Tabynov. Development and Evaluation of a Live Attenuated Egg-Based Camelpox Vaccine. Front. Vet. Sci., 16 August 2021.https://doi.org/10.3389/fvets.2021.721023.

32. Kenneth B Yeh, Falgunee K Parekh, Lyazzat Musralina, Ablay Sansyzbai, Kairat Tabynov, Zhanna Shapieva, Allen L Richards, John Hay. A Case History in Cooperative Biological Research: Compendium of Studies and Program Analyses in Kazakhstan. Trop. Med. Infect. Dis. 2019, 4(4), 136. https://doi.org/10.3390/tropicalmed4040136.

33. Santosh Dhakal, Jagadish Hiremath, Kathryn Bondra, Yashavanth S Lakshmanappa, Duan-Liang Shyu, Kang Ouyang, Kyung-il Kang, Basavaraj Binjawadagi, Jonathan Goodman, Kairat Tabynov, Steven Krakowka, Balaji Narasimhan, Chang Won Lee, Gourapura J Renukaradhya. Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs. Journal of Controlled Release Volume 247, 10 February 2017, Pages 194-205.https://doi.org/10.1016/j.jconrel.2016.12.039.

34. K Tabynov, Z Kydyrbayev, S Ryskeldinova, B Yespembetov, N Syrymkyzy, I Akzhunusova, A Sansyzbay. Safety of the novel vector vaccine against Brucella abortus based on recombinant influenza viruses expressing Brucella L7/L12 and OMP16 proteins, in cattle. J Vaccines Immun 1 (1): 001. https://www.peertechzpublications.com/Vaccines-Immunology/JVI-1-101.pdf.

35. Muratbay Mambetaliyev. Kairat Tabynov, Abylay Sansyzbay, Nurlan Sandybayev. The pathogenicity of swan derived H5N1 virus in birds and mammals and its gene analysis. Virology Journal,2014.

36. K Tabynov, Zh Kydyrbayev, Sh Ryskeldinova, N Assanzhanova, A Sansyzbay. Duration of the protective immune response after prime and booster vaccination of yearlings with a live modified cold-adapted viral vaccine against equine influenza. j.vaccine.2014.03.095. https://doi.org/10.1016/j.vaccine.2014.03.095.

37. Olga Gromova, Aikerm Doschanova, Vyacheslav Lokshin, Ainur Tuletova, Galina Grebennikova, Laura Daniyarova, Gulnaz Kaishibayeva, Tair Nurpeissov, Viktoriya Khan, Yuliya Semenova, Albina Chibisova, Natalia Suzdalskaya, Zhanara Aitaly, Natalia Glushkova. Vitamin D deficiency in Kazakhstan: Cross-Sectional study. Jou rnal of Steroid Biochemistry and Molecular Biology, Vol. 199 (2020) 105565. https://doi.org/10.1016/j.jsbmb.2019.105565.
 
38. Tair Nurpeissov, Temyrlan Nurpeissov, Gulzada Abdushukurova, Temyrzhan Nurpeissov, Aigul Zhaksylykova. Availability and compliance to basic therapy of bronchial asthma in rural region of Kazakhstan. European Respiratory Journal 2013 42: P3835.

39. Nurpeissov, T., Nurpeissov, T., Abdushukurova, G. et al. Tolerability of budesonide/formoterol in patients of Kazakhstan rural regions. Clin Transl Allergy 5, P21 (2015). https://doi.org/10.1186/2045-7022-5-S2-P21.

40. Zhangir Tulekov, Anar Dushpanova, Zhanna Romanova, Aleksandr Sokolov, Valeriya Sokolova, Tair Nurpeisov .Exposure to nickel from the metal equipment in the gym F1000 research 2019; 8:68. https://f1000research.com/articles/8-68.

41. Gulzada Abdushukurova, Tair Nurpeissov, M Gazaliyeva, B Zhumabekova, S Akhmetova, N Glushkova.Profile Of Asthmatic Patients In South Kazakhstan Region: A Cross-Sectional Study .International online journal «Research Journal of Pharmaceutical, Biological and Chemical Sciences (RJPBCS) ». – №6 (6), 2015 y. – P.73-81.ISSN 0975-8585.

42. Tabynov K., Khairullin B., Kydyrbayev Zh., Sandybayev N., Stukova M., Erofeeva M., Shurygina A.P., Kiselev O., Mamadaliev S., Sansyzbay A. Preliminary assessment of safety and immunogenicity of an inactivated whole-virion vaccine against influenza А(H1N1) pdm09 containing aluminum hydroxide adjuvant: a randomized, blinded phase I clinical study. Journal of Vaccines & Vaccination. 2013, 4(7):205.

43.Saltabayeva U, Garib V, Morenko M, Rosenson R, Ispayeva Z, Gatauova M, Zulus L, Karaulov A, Gastager F, Valenta R. Greater Real-Life Diagnostic Efficacy of Allergen Molecule-Based Diagnosis for Prescription of Immunotherapy in an Area with Multiple Pollen Exposure. Int Arch Allergy Immunol. 2017;173(2):93-98.

44.Saltabayeva U, Morenko M, Garib V, Nurzhanat H. Comparative effectiveness and safety of different allergen-specific immunotherapy types in pollinosis. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2016; 7(4):2691-2697.

45.Turebekov N, et al. Prevalence of Rickettsia species in ticks including identification of unknown  pecies in two regions in Kazakhstan. Parasites & vectors. 2019;12(1):197.
 
46.Turebekov N, et al. Seroepidemiological and molecular investigations of infections with Crimean-Congo haemorrhagic fever virus in Kazakhstan. Int J Infect Dis. 2019:121-127.
 
  

Media about us

1.https://the-steppe.com/lyudi/kak-razrabatyvayut-vakcinu-protiv-koronavirusa-i-kto-zanimaetsya-etim-v-kazahstane?fbclid=IwAR3fJCfAUPU5ubcIRhDKBLo-bDQWwLwSJzOCVmjbYXUdvyw8--dFam4GWm8#

2.https://aikyn.kz/63061/vakcina-salghyzyp-uekimetting-nazaryn-awdarghym-keldi-virwsolog-vakcinolog-professor-irwsolog-vakcinolog-professor/?fbclid=IwAR32QiXDFEJsnQD5NawVuOeApDbG94knuFhgfDX5arRhufhbTup8LnR0yro

3.https://ru.sputnik.kz/health/20200922/15026632/Kazakhstan-razrabatyvaet-bezynektsionnuyu-vaktsinu-ot-koronavirusa.html?fbclid=IwAR3TYPP1uxEHq9-gKRJ7Phvt24qazVu7A3wTsyTmn84ppYGqOyr5xdYymNA

4.https://ru.sputnik.kz/radio/20201102/15367462/kazakhstan-vaktsina-allergiya.html?fbclid=IwAR3fBRZvs7tUokPGr8VM1f8Uenk-cEdqjpipAO2mCd-S8l_HZSaWzbg3yu4

5.https://24.kz/ru/news/social/item/434581-kazakhstanskaya-vaktsina-ot-koronavirusa-poluchila-nazvanie-naruvax-c-19?fbclid=IwAR31FMBiX9NaQPHNtMoV2d41PcY0YNl5Gm1YI3DtIC9hmy5QramImzo3Ugo

6. https://tengrinews.kz/kazakhstan_news/kazahstanskiy-uchenyiy-vvel-vtoruyu-vaktsinu-protiv-420864/?fbclid=IwAR1xfTeZIz1mb_GS5S1oKeIKyCDXhkhbu_spShUHUbFVhorQUGxdOf1_pCw

7. https://tengrinews.kz/kazakhstan_news/nazarbaev-nazval-imena-molodyih-kazahstantsev-kotoryimi-422897/?fbclid=IwAR1k2xfpuJz-diG5dAQXVxnIOVi0UvLufpGYPEgbCjQbd0ZBCtYt0-uU8Ac

8. https://www.youtube.com/watch?v=6z-6gf1THeQ

9.https://anatili.kazgazeta.kz/news/58866?fbclid=IwAR3BOwR11QSMS12aMjIFJvJT4L1Q_bT4dxGd3ar22ftJNHbFyvwzgA1I4aE

10.https://www.kazpravda.kz/news/prezident2/eshche-dve-kazahstanskie-vaktsini-ot-covid-19-vklucheni-v-reestr-voz---tokaev?fbclid=IwAR0GmC5ORarN-Jl5e3NSABQOauZ2an-cX5u1HaTEkBgcv4Z5IE3ya4ExNDA

11. https://www.kazpravda.kz/news/obshchestvo/chto-izvestno-o-novoi-kazahstanskoi-vaktsine-naruvax-c19-ot-koronavirusa

12. https://tengrinews.kz/kazakhstan_news/vaktsinu-protiv-covid-19-koshek-prezentovali-nur-sultane-451862/

13. https://ru.sputnik.kz/health/20211021/18472241/Pervuyu-kazakhstanskuyu-vaktsinu-protiv-COVID-19-dlya-koshek-prezentovali-v-Nur-Sultane.html

14. https://www.kt.kz/rus/covid-19/v_kazahstane_sozdali_vaktsinu_protiv_covid-19_dlya_koshek_1377923467.html

15. https://informburo.kz/novosti/kazahstanskuyu-vakcinu-ot-koronavirusa-dlya-koshek-predstavili-v-nur-sultane

16. https://tass.ru/obschestvo/12739301

17. https://inbusiness.kz/ru/last/na-vystavke-kazagro-pokazali-vakcinu-protiv-covid-19-dlya-koshek

18. https://newtimes.kz/obshchestvo/138415-vaktsinu-protiv-kvi-dlia-koshek-prezentovali-v-nur-sultane

19. https://vestikavkaza.ru/news/kazahstan-sozdal-pervuu-otecestvennuu-antikoronavirusnuu-vakcinu-dla-kosek.html

20. https://www.nur.kz/health/coronavirus/1938189-tri-novye-vaktsiny-protiv-koronavirusa-poyavyatsya-v-kazahstane-odnoy-iz-nih-mozhno-privitsya-doma/

21. https://orda.kz/v-kazahstane-razrabotali-vakcinu-ot-covid-19-dlja-koshek-chto-o-nej-izvestno/

22.https://ratel.kz/kaz/v_nur_sultane_predstavili_vaktsinu_ot_covid_19_dlja_koshek

23. https://365info.kz/2021/10/kiski-tozhe-v-zone-riska-vaktsinu-ot-kvi-vypustili-dlya-koshek-v-kazahstane

24. https://www.sb.by/articles/v-kazakhstane-razrabotali-veterinarnuyu-vaktsinu-ot-koronavirusa-dlya-koshek.html?amp=1

25. https://ulysmedia.kz/news/1531-kazakhstanskuiu-vaktsinu-ot-covid-19-dlia-koshek-prezentovali-v-stolitse/

26. https://www.kazpravda.kz/news/obshchestvo/vaktsinu-protiv-covid-19-dlya-pushnih-zhivotnih-razrabotali-kazahstanskie-virusologi

27. https://informburo.kz/novosti/zooparki-kazahstana-mogut-besplatno-vakcinirovat-tigrov-i-lvov-protiv-covid-19

28. https://paryz.kz/kazakhstan-news/12496-kazakhstanskii-uchenyi-prizval-vladeltsev-zooparkov-vaktsinirovat-tigrov-i-lvov

29. https://orda.kz/zooparkam-kazahstana-predlozhili-besplatno-vakcinirovat-predstavitelej-koshachih-ot-covid-19/

30. https://www.caravan.kz/news/budut-li-vakcinirovat-zhivotnykh-ot-koronavirusa-rasskazali-v-zooparke-almaty-755537/

31. https://www.youtube.com/watch?v=_oyeoIrgZzo

32. https://youtu.be/o1yr1UcCPzM

33. https://youtu.be/C24KjZcQMoY

34. https://youtu.be/iz6DgahEgws

35. https://youtu.be/ptwq-HsBYKE

36. https://youtu.be/C4AWmcp5PZE

37. https://youtu.be/Vd8ljAbfnK8

38. https://youtu.be/xk0q8vpklxA

39. https://youtu.be/nUD8lzVC1GM

40. https://youtu.be/lFN8egJv-kE

41. https://youtu.be/cSYBfr4E6rY

42. https://youtu.be/YXkTWhy-bro

43. https://pharmnewskz.com/ru/news/kazahstanskaya-vakcina-ot-allergii-proshla-doklinicheskie-ispytaniya_20532

44. https://www.ndda.kz/pages/kazakhstanskaya-vaktsina-ot-allergii-proshla-doklinicheskie-ispytaniya_1668686165